Jiang Jin, Liu Boyang, Hothi Sandeep S
Heart and Lung Centre, New Cross Hospital, Wolverhampton, UK.
Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
Cardiol Res Pract. 2022 Feb 27;2022:1910841. doi: 10.1155/2022/1910841. eCollection 2022.
Herceptin (trastuzumab) is a recombinant, humanized, monoclonal antibody that targets the human epidermal growth factor receptor 2 (HER2) and is used in the treatment of HER2-positive breast and gastric cancers. However, it carries a risk of cardiotoxicity, manifesting as left ventricular (LV) systolic dysfunction, conventionally assessed for by transthoracic echocardiography. Clinical surveillance of cardiac function and discontinuation of trastuzumab at an early stage of LV systolic dysfunction allow for the timely initiation of heart failure drug therapies that can result in the rapid recovery of cardiac function in most patients. Often considered the reference standard for the noninvasive assessment of cardiac volume and function, cardiac magnetic resonance (CMR) imaging has superior reproducibility and accuracy compared to other noninvasive imaging modalities. However, due to limited availability, it is not routinely used in the serial assessment of cardiac function in patients receiving trastuzumab. In this article, we review the diagnostic and prognostic role of CMR in trastuzumab-mediated cardiotoxicity.
赫赛汀（曲妥珠单抗）是一种重组人源化单克隆抗体，靶向人表皮生长因子受体2（HER2），用于治疗HER2阳性乳腺癌和胃癌。然而，它存在心脏毒性风险，表现为左心室（LV）收缩功能障碍，传统上通过经胸超声心动图进行评估。对心功能进行临床监测，并在LV收缩功能障碍的早期停用曲妥珠单抗，可及时启动心力衰竭药物治疗，这能使大多数患者的心功能迅速恢复。心脏磁共振（CMR）成像常被视为心脏容积和功能无创评估的参考标准，与其他无创成像方式相比，其具有更高的可重复性和准确性。然而，由于可用性有限，它并未常规用于接受曲妥珠单抗治疗患者的心功能系列评估。在本文中，我们综述了CMR在曲妥珠单抗介导的心脏毒性中的诊断和预后作用。
